English

Summit Therapeutics Inc.

EDGAR

SMMT Quarterly report (10-Q) · filed 2026-07-23

Annual consolidated revenue for 2024: about USD 0, using the latest reported figures. The previous period, 2023, was about USD 0.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2024 Q4 · USD

Exact inputs and evidence

Revenue: 0 USD Source
Revenue: 0 USD Source

Operating cash flow

-48.7 million USD

2024 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -142106000 USD Source
Operating Cash Flow: -93433000 USD Source

Free cash flow

-48.7 million USD

2024 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -142106000 USD Source
Operating Cash Flow: -93433000 USD Source
Capital Expenditure: 139000 USD Source
Capital Expenditure: 125000 USD Source

Cash and cash equivalents: 419 million USD 2026-06-30 Source
Exact value

419365000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 793 million shares 2026-06-30 Source
Exact value

793120362 shares

Reported share-count change

6.77% · 50.3 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

742806672 shares · 2025-06-30· Source
793120362 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-856 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -231793000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -1079586000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -860414000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -189424000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -215700000 USD · 2026-04-01 – 2026-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-07-23.

Financial data available through: 2024-12-31.

Financial coverage is incomplete. Newer filings are recorded, but comparable financial figures for those periods are not available here yet.

Coverage by financial measure

Revenue: 7 of 11 periods available· newest 2024-12-31
Operating income: 7 of 11 periods available· newest 2024-12-31
Net income: 7 of 11 periods available· newest 2024-12-31
Operating cash flow: 7 of 11 periods available· newest 2024-12-31
Capital expenditure: 7 of 11 periods available· newest 2024-12-31
Total assets: 6 of 11 periods available· newest 2024-12-31
Total liabilities: 6 of 11 periods available· newest 2024-12-31
Current assets: 6 of 11 periods available· newest 2024-12-31
Current liabilities: 6 of 11 periods available· newest 2024-12-31
Cash and cash equivalents: 6 of 11 periods available· newest 2024-12-31
long term debt: No compatible figures in this window
Shares outstanding: 6 of 11 periods available· newest 2024-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
USD 0

Prior period

USD 0

2023-01-01 – 2023-12-31
Current period

USD 0

2024-01-01 – 2024-12-31

Exact inputs and evidence

0 − 0 = 0 USD

0 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
0 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Summit Therapeutics Inc. · 2024-12-31 Summit Therapeutics Inc. (edgar:1599298) Year-over-year change in Revenue: 0 USD Concept: fundies:Revenue Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929825000048/smmt-20241231.htm#1152254 Filing: 000159929825000048 Input fundies:Revenue: 0 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929825000048/smmt-20241231.htm#1153144 Filing: 000159929825000048
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 393.61 million

Prior period

−USD 614.93 million

2023-01-01 – 2023-12-31
Current period

−USD 221.32 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-221315000 − -614928000 = 393613000 USD

-614928000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-221315000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Summit Therapeutics Inc. · 2024-12-31 Summit Therapeutics Inc. (edgar:1599298) Year-over-year change in Net income: 393613000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -221315000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000015/smmt-20251231.htm#1615086 Filing: 000159929826000015 Input fundies:NetIncome: -614928000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000015/smmt-20251231.htm#1615938 Filing: 000159929826000015
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 65.35 million

Prior period

−USD 76.76 million

2023-01-01 – 2023-12-31
Current period

−USD 142.11 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-142106000 − -76760000 = -65346000 USD

-76760000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-142106000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Summit Therapeutics Inc. · 2024-12-31 Summit Therapeutics Inc. (edgar:1599298) Year-over-year change in Operating cash flow: -65346000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -142106000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000015/smmt-20251231.htm#1302423 Filing: 000159929826000015 Input fundies:OperatingCashFlow: -76760000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000015/smmt-20251231.htm#1303077 Filing: 000159929826000015
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+8.6%

Prior period

USD 128,000

2023-01-01 – 2023-12-31
Current period

USD 139,000

2024-01-01 – 2024-12-31

Exact inputs and evidence

139000 − 128000 = 11000 USD

128000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
139000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Summit Therapeutics Inc. · 2024-12-31 Summit Therapeutics Inc. (edgar:1599298) Year-over-year change in Capital expenditure: 11000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 139000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000015/smmt-20251231.htm#1309926 Filing: 000159929826000015 Input fundies:CapitalExpenditure: 128000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000015/smmt-20251231.htm#1310486 Filing: 000159929826000015
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2024 2024-01-01 – 2024-12-31

Revenue USD 0
Operating costs Derived USD 226 million
Operating income −USD 226 million
Tax, interest and other Derived −USD 4.68 million
Net income −USD 221.32 million

Cash

Operating cash flow −USD 142.11 million
Capital expenditure USD 139,000
Free cash flow Derived −USD 142.25 million

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2019 Net income was higher than operating income, so the split is not drawn.
2019 Operating loss: operating costs were 3,798% of revenue.
2020 Operating loss: operating costs were 6,285% of revenue.
2021 Operating loss: operating costs were 4,864% of revenue.
2022 Operating loss: operating costs were 10,325% of revenue.
2023 Not shown: operating income or net income is not reported.
2024 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2019 2018-02-01 – 2019-01-31	57088000	51699000 Derived	5389000	-5480000 Derived	10869000	-35263000 Derived	Source 2018-02-01 – 2019-01-31: 57088000 USD Inspect Revenue Open source 2018-02-01 – 2019-01-31: 5389000 USD Inspect Operating Income Open source 2018-02-01 – 2019-01-31: 10869000 USD Inspect Net Income Open source 2018-02-01 – 2019-01-31: -35106000 USD Inspect Operating Cash Flow Open source 2018-02-01 – 2019-01-31: 157000 USD Inspect Capital Expenditure Open source
2019 2019-02-01 – 2019-12-31	743000	28216000 Derived	-27473000	1654000 Derived	-29127000	-20962000 Derived	Source 2019-02-01 – 2019-12-31: 743000 USD Inspect Revenue Open source 2019-02-01 – 2019-12-31: -27473000 USD Inspect Operating Income Open source 2019-02-01 – 2019-12-31: -29127000 USD Inspect Net Income Open source 2019-02-01 – 2019-12-31: -20757000 USD Inspect Operating Cash Flow Open source 2019-02-01 – 2019-12-31: 205000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	860000	54053000 Derived	-53193000	-496000 Derived	-52697000	-48532000 Derived	Source 2020-01-01 – 2020-12-31: 860000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -53193000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -52697000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -48111000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 421000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	1809000	87995000 Derived	-86186000	2416000 Derived	-88602000	-72893000 Derived	Source 2021-01-01 – 2021-12-31: 1809000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -86186000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -88602000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -72587000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 306000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	705000	72794000 Derived	-72089000	6693000 Derived	-78782000	-42206000 Derived	Source 2022-01-01 – 2022-12-31: 705000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -72089000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -78782000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -41582000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 624000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	0	609650000 Derived	-609650000	5278000 Derived	-614928000	-76888000 Derived	Source 2023-01-01 – 2023-12-31: 0 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -609650000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -614928000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -76760000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 128000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	0	225998000 Derived	-225998000	-4683000 Derived	-221315000	-142245000 Derived	Source 2024-01-01 – 2024-12-31: 0 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -225998000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -221315000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -142106000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 139000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2024

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-01-31	Revenue	57088000	Revenue: 57088000 Open source
20192019-12-31	Revenue	743000	Revenue: 743000 Open source
20202020-12-31	Revenue	860000	Revenue: 860000 Open source
20212021-12-31	Revenue	1809000	Revenue: 1809000 Open source
20222022-12-31	Revenue	705000	Revenue: 705000 Open source
20232023-12-31	Revenue	0	Revenue: 0 Open source
20242024-12-31	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2023

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20192019-01-31	Year over year	No prior comparable period	Revenue: 57088000 Open source
20192019-12-31	Year over year	No prior comparable period	Revenue: 743000 Open source
20202020-12-31	Year over year	No prior comparable period	Revenue: 860000 Open source
20212021-12-31	Year over year	110.3%	Revenue: 1809000 Open source Revenue: 860000 Open source
20222022-12-31	Year over year	-61%	Revenue: 705000 Open source Revenue: 1809000 Open source
20232023-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 705000 Open source
20242024-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -10,225.4% 2022

Net margin -11,174.8% 2022

Free cash flow margin -5,986.7% 2022

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20192019-01-31	Operating margin	9.4%	Operating Income: 5389000 Open source Revenue: 57088000 Open source
20192019-12-31	Operating margin	-3,697.6%	Operating Income: -27473000 Open source Revenue: 743000 Open source
20202020-12-31	Operating margin	-6,185.2%	Operating Income: -53193000 Open source Revenue: 860000 Open source
20212021-12-31	Operating margin	-4,764.3%	Operating Income: -86186000 Open source Revenue: 1809000 Open source
20222022-12-31	Operating margin	-10,225.4%	Operating Income: -72089000 Open source Revenue: 705000 Open source
20232023-12-31	Operating margin	Not reported	Operating Income: -609650000 Open source Revenue: 0 Open source
20242024-12-31	Operating margin	Not reported	Operating Income: -225998000 Open source Revenue: 0 Open source
20192019-01-31	Net margin	19%	Net Income: 10869000 Open source Revenue: 57088000 Open source
20192019-12-31	Net margin	-3,920.2%	Net Income: -29127000 Open source Revenue: 743000 Open source
20202020-12-31	Net margin	-6,127.6%	Net Income: -52697000 Open source Revenue: 860000 Open source
20212021-12-31	Net margin	-4,897.8%	Net Income: -88602000 Open source Revenue: 1809000 Open source
20222022-12-31	Net margin	-11,174.8%	Net Income: -78782000 Open source Revenue: 705000 Open source
20232023-12-31	Net margin	Not reported	Net Income: -614928000 Open source Revenue: 0 Open source
20242024-12-31	Net margin	Not reported	Net Income: -221315000 Open source Revenue: 0 Open source
20192019-01-31	Free cash flow margin	-61.8%	Revenue: 57088000 Open source Operating Cash Flow: -35106000 Open source Capital Expenditure: 157000 Open source
20192019-12-31	Free cash flow margin	-2,821.3%	Revenue: 743000 Open source Operating Cash Flow: -20757000 Open source Capital Expenditure: 205000 Open source
20202020-12-31	Free cash flow margin	-5,643.3%	Revenue: 860000 Open source Operating Cash Flow: -48111000 Open source Capital Expenditure: 421000 Open source
20212021-12-31	Free cash flow margin	-4,029.5%	Revenue: 1809000 Open source Operating Cash Flow: -72587000 Open source Capital Expenditure: 306000 Open source
20222022-12-31	Free cash flow margin	-5,986.7%	Revenue: 705000 Open source Operating Cash Flow: -41582000 Open source Capital Expenditure: 624000 Open source
20232023-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -76760000 Open source Capital Expenditure: 128000 Open source
20242024-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -142106000 Open source Capital Expenditure: 139000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -142.1M 2024

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-01-31	Operating cash flow	-35106000	Operating Cash Flow: -35106000 Open source
20192019-12-31	Operating cash flow	-20757000	Operating Cash Flow: -20757000 Open source
20202020-12-31	Operating cash flow	-48111000	Operating Cash Flow: -48111000 Open source
20212021-12-31	Operating cash flow	-72587000	Operating Cash Flow: -72587000 Open source
20222022-12-31	Operating cash flow	-41582000	Operating Cash Flow: -41582000 Open source
20232023-12-31	Operating cash flow	-76760000	Operating Cash Flow: -76760000 Open source
20242024-12-31	Operating cash flow	-142106000	Operating Cash Flow: -142106000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -142.2M 2024

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-01-31	Free cash flow	-35263000	Operating Cash Flow: -35106000 Open source Capital Expenditure: 157000 Open source
20192019-12-31	Free cash flow	-20962000	Operating Cash Flow: -20757000 Open source Capital Expenditure: 205000 Open source
20202020-12-31	Free cash flow	-48532000	Operating Cash Flow: -48111000 Open source Capital Expenditure: 421000 Open source
20212021-12-31	Free cash flow	-72893000	Operating Cash Flow: -72587000 Open source Capital Expenditure: 306000 Open source
20222022-12-31	Free cash flow	-42206000	Operating Cash Flow: -41582000 Open source Capital Expenditure: 624000 Open source
20232023-12-31	Free cash flow	-76888000	Operating Cash Flow: -76760000 Open source Capital Expenditure: 128000 Open source
20242024-12-31	Free cash flow	-142245000	Operating Cash Flow: -142106000 Open source Capital Expenditure: 139000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

10.7% 2024

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2019-01-31	Liabilities / assets	Not reported	No source recorded
20192019-12-31	Liabilities / assets	18.1%	Total Liabilities: 17385000 Open source Total Assets: 96248000 Open source
20202020-12-31	Liabilities / assets	22.5%	Total Liabilities: 23045000 Open source Total Assets: 102498000 Open source
20212021-12-31	Liabilities / assets	26.5%	Total Liabilities: 30090000 Open source Total Assets: 113374000 Open source
20222022-12-31	Liabilities / assets	80.9%	Total Liabilities: 537514000 Open source Total Assets: 664168000 Open source
20232023-12-31	Liabilities / assets	61.7%	Total Liabilities: 125257000 Open source Total Assets: 202949000 Open source
20242024-12-31	Liabilities / assets	10.7%	Total Liabilities: 46812000 Open source Total Assets: 435560000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

10.15× 2024

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2019-01-31	Current assets / current liabilities	Not reported	No source recorded
20192019-12-31	Current assets / current liabilities	5.78×	Current Assets: 79628000 Open source Current Liabilities: 13767000 Open source
20202020-12-31	Current assets / current liabilities	4.41×	Current Assets: 87674000 Open source Current Liabilities: 19890000 Open source
20212021-12-31	Current assets / current liabilities	3.8×	Current Assets: 97312000 Open source Current Liabilities: 25623000 Open source
20222022-12-31	Current assets / current liabilities	16.93×	Current Assets: 656712000 Open source Current Liabilities: 38782000 Open source
20232023-12-31	Current assets / current liabilities	9.3×	Current Assets: 189712000 Open source Current Liabilities: 20405000 Open source
20242024-12-31	Current assets / current liabilities	10.15×	Current Assets: 423750000 Open source Current Liabilities: 41729000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2019 2018-02-01 – 2019-01-31	USD 10.87 million Exact value Exact value: 10869000 USD 2018-02-01 – 2019-01-31: 10869000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Summit Therapeutics Inc. · 2019-01-31 Summit Therapeutics Inc. (edgar:1599298) Net Income: 10869000 USD Concept: fundies:NetIncome Period: 2018-02-01 to 2019-01-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298/explain?concept=fundies%3ANetIncome&period=2019-01-31&surface=latest&period_type=duration&start=2018-02-01&unit=USD&dimensions= Input fundies:NetIncome: 10869000 USD (2018-02-01 to 2019-01-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929821000011/smmt-20201231.htm#1923450 Filing: 000159929821000011 The citation records this snapshot. The page link may show a newer release later.	−USD 35.11 million Exact value Exact value: -35106000 USD 2018-02-01 – 2019-01-31: -35106000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Summit Therapeutics Inc. · 2019-01-31 Summit Therapeutics Inc. (edgar:1599298) Operating Cash Flow: -35106000 USD Concept: fundies:OperatingCashFlow Period: 2018-02-01 to 2019-01-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298/explain?concept=fundies%3AOperatingCashFlow&period=2019-01-31&surface=latest&period_type=duration&start=2018-02-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -35106000 USD (2018-02-01 to 2019-01-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929821000011/smmt-20201231.htm#1535191 Filing: 000159929821000011 The citation records this snapshot. The page link may show a newer release later.	USD 157,000 Exact value Exact value: 157000 USD 2018-02-01 – 2019-01-31: 157000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Summit Therapeutics Inc. · 2019-01-31 Summit Therapeutics Inc. (edgar:1599298) Capital Expenditure: 157000 USD Concept: fundies:CapitalExpenditure Period: 2018-02-01 to 2019-01-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298/explain?concept=fundies%3ACapitalExpenditure&period=2019-01-31&surface=latest&period_type=duration&start=2018-02-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 157000 USD (2018-02-01 to 2019-01-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929821000011/smmt-20201231.htm#1543499 Filing: 000159929821000011 The citation records this snapshot. The page link may show a newer release later.	−USD 35.26 million Calculation and evidence -35106000 − 157000 USD Exact free cash flow: -35263000 USD 2018-02-01 – 2019-01-31: -35106000 USD · Inspect Operating Cash Flow · Source 2018-02-01 – 2019-01-31: 157000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Summit Therapeutics Inc. · 2019-01-31 Summit Therapeutics Inc. (edgar:1599298) Free cash flow: -35263000 USD Concept: free-cash-flow Period: 2018-02-01 to 2019-01-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -35106000 USD (2018-02-01 to 2019-01-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929821000011/smmt-20201231.htm#1535191 Filing: 000159929821000011 Input fundies:CapitalExpenditure: 157000 USD (2018-02-01 to 2019-01-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929821000011/smmt-20201231.htm#1543499 Filing: 000159929821000011 The citation records this snapshot. The page link may show a newer release later.
2019 2019-02-01 – 2019-12-31	−USD 29.13 million Exact value Exact value: -29127000 USD 2019-02-01 – 2019-12-31: -29127000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Summit Therapeutics Inc. · 2019-12-31 Summit Therapeutics Inc. (edgar:1599298) Net Income: -29127000 USD Concept: fundies:NetIncome Period: 2019-02-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-02-01&unit=USD&dimensions= Input fundies:NetIncome: -29127000 USD (2019-02-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929821000011/smmt-20201231.htm#1922284 Filing: 000159929821000011 The citation records this snapshot. The page link may show a newer release later.	−USD 20.76 million Exact value Exact value: -20757000 USD 2019-02-01 – 2019-12-31: -20757000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Summit Therapeutics Inc. · 2019-12-31 Summit Therapeutics Inc. (edgar:1599298) Operating Cash Flow: -20757000 USD Concept: fundies:OperatingCashFlow Period: 2019-02-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-02-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -20757000 USD (2019-02-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929821000011/smmt-20201231.htm#1534142 Filing: 000159929821000011 The citation records this snapshot. The page link may show a newer release later.	USD 205,000 Exact value Exact value: 205000 USD 2019-02-01 – 2019-12-31: 205000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Summit Therapeutics Inc. · 2019-12-31 Summit Therapeutics Inc. (edgar:1599298) Capital Expenditure: 205000 USD Concept: fundies:CapitalExpenditure Period: 2019-02-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-02-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 205000 USD (2019-02-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929821000011/smmt-20201231.htm#1542547 Filing: 000159929821000011 The citation records this snapshot. The page link may show a newer release later.	−USD 20.96 million Calculation and evidence -20757000 − 205000 USD Exact free cash flow: -20962000 USD 2019-02-01 – 2019-12-31: -20757000 USD · Inspect Operating Cash Flow · Source 2019-02-01 – 2019-12-31: 205000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Summit Therapeutics Inc. · 2019-12-31 Summit Therapeutics Inc. (edgar:1599298) Free cash flow: -20962000 USD Concept: free-cash-flow Period: 2019-02-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -20757000 USD (2019-02-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929821000011/smmt-20201231.htm#1534142 Filing: 000159929821000011 Input fundies:CapitalExpenditure: 205000 USD (2019-02-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929821000011/smmt-20201231.htm#1542547 Filing: 000159929821000011 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 52.7 million Exact value Exact value: -52697000 USD 2020-01-01 – 2020-12-31: -52697000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Summit Therapeutics Inc. · 2020-12-31 Summit Therapeutics Inc. (edgar:1599298) Net Income: -52697000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -52697000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929822000147/smmt-20211231.htm#887494 Filing: 000159929822000147 The citation records this snapshot. The page link may show a newer release later.	−USD 48.11 million Exact value Exact value: -48111000 USD 2020-01-01 – 2020-12-31: -48111000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Summit Therapeutics Inc. · 2020-12-31 Summit Therapeutics Inc. (edgar:1599298) Operating Cash Flow: -48111000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -48111000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929822000147/smmt-20211231.htm#510703 Filing: 000159929822000147 The citation records this snapshot. The page link may show a newer release later.	USD 421,000 Exact value Exact value: 421000 USD 2020-01-01 – 2020-12-31: 421000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Summit Therapeutics Inc. · 2020-12-31 Summit Therapeutics Inc. (edgar:1599298) Capital Expenditure: 421000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 421000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929822000147/smmt-20211231.htm#514191 Filing: 000159929822000147 The citation records this snapshot. The page link may show a newer release later.	−USD 48.53 million Calculation and evidence -48111000 − 421000 USD Exact free cash flow: -48532000 USD 2020-01-01 – 2020-12-31: -48111000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 421000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Summit Therapeutics Inc. · 2020-12-31 Summit Therapeutics Inc. (edgar:1599298) Free cash flow: -48532000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -48111000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929822000147/smmt-20211231.htm#510703 Filing: 000159929822000147 Input fundies:CapitalExpenditure: 421000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929822000147/smmt-20211231.htm#514191 Filing: 000159929822000147 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 88.6 million Exact value Exact value: -88602000 USD 2021-01-01 – 2021-12-31: -88602000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Summit Therapeutics Inc. · 2021-12-31 Summit Therapeutics Inc. (edgar:1599298) Net Income: -88602000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -88602000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929823000034/smmt-20221231.htm#1746126 Filing: 000159929823000034 The citation records this snapshot. The page link may show a newer release later.	−USD 72.59 million Exact value Exact value: -72587000 USD 2021-01-01 – 2021-12-31: -72587000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Summit Therapeutics Inc. · 2021-12-31 Summit Therapeutics Inc. (edgar:1599298) Operating Cash Flow: -72587000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -72587000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929823000034/smmt-20221231.htm#1358307 Filing: 000159929823000034 The citation records this snapshot. The page link may show a newer release later.	USD 306,000 Exact value Exact value: 306000 USD 2021-01-01 – 2021-12-31: 306000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Summit Therapeutics Inc. · 2021-12-31 Summit Therapeutics Inc. (edgar:1599298) Capital Expenditure: 306000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 306000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929823000034/smmt-20221231.htm#1361795 Filing: 000159929823000034 The citation records this snapshot. The page link may show a newer release later.	−USD 72.89 million Calculation and evidence -72587000 − 306000 USD Exact free cash flow: -72893000 USD 2021-01-01 – 2021-12-31: -72587000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 306000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Summit Therapeutics Inc. · 2021-12-31 Summit Therapeutics Inc. (edgar:1599298) Free cash flow: -72893000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -72587000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929823000034/smmt-20221231.htm#1358307 Filing: 000159929823000034 Input fundies:CapitalExpenditure: 306000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929823000034/smmt-20221231.htm#1361795 Filing: 000159929823000034 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 78.78 million Exact value Exact value: -78782000 USD 2022-01-01 – 2022-12-31: -78782000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Summit Therapeutics Inc. · 2022-12-31 Summit Therapeutics Inc. (edgar:1599298) Net Income: -78782000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -78782000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929825000048/smmt-20241231.htm#1699914 Filing: 000159929825000048 The citation records this snapshot. The page link may show a newer release later.	−USD 41.58 million Exact value Exact value: -41582000 USD 2022-01-01 – 2022-12-31: -41582000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Summit Therapeutics Inc. · 2022-12-31 Summit Therapeutics Inc. (edgar:1599298) Operating Cash Flow: -41582000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -41582000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929825000048/smmt-20241231.htm#1364178 Filing: 000159929825000048 The citation records this snapshot. The page link may show a newer release later.	USD 624,000 Exact value Exact value: 624000 USD 2022-01-01 – 2022-12-31: 624000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Summit Therapeutics Inc. · 2022-12-31 Summit Therapeutics Inc. (edgar:1599298) Capital Expenditure: 624000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 624000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929825000048/smmt-20241231.htm#1367479 Filing: 000159929825000048 The citation records this snapshot. The page link may show a newer release later.	−USD 42.21 million Calculation and evidence -41582000 − 624000 USD Exact free cash flow: -42206000 USD 2022-01-01 – 2022-12-31: -41582000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 624000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Summit Therapeutics Inc. · 2022-12-31 Summit Therapeutics Inc. (edgar:1599298) Free cash flow: -42206000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -41582000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929825000048/smmt-20241231.htm#1364178 Filing: 000159929825000048 Input fundies:CapitalExpenditure: 624000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929825000048/smmt-20241231.htm#1367479 Filing: 000159929825000048 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 614.93 million Exact value Exact value: -614928000 USD 2023-01-01 – 2023-12-31: -614928000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Summit Therapeutics Inc. · 2023-12-31 Summit Therapeutics Inc. (edgar:1599298) Net Income: -614928000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -614928000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000015/smmt-20251231.htm#1615938 Filing: 000159929826000015 The citation records this snapshot. The page link may show a newer release later.	−USD 76.76 million Exact value Exact value: -76760000 USD 2023-01-01 – 2023-12-31: -76760000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Summit Therapeutics Inc. · 2023-12-31 Summit Therapeutics Inc. (edgar:1599298) Operating Cash Flow: -76760000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -76760000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000015/smmt-20251231.htm#1303077 Filing: 000159929826000015 The citation records this snapshot. The page link may show a newer release later.	USD 128,000 Exact value Exact value: 128000 USD 2023-01-01 – 2023-12-31: 128000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Summit Therapeutics Inc. · 2023-12-31 Summit Therapeutics Inc. (edgar:1599298) Capital Expenditure: 128000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 128000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000015/smmt-20251231.htm#1310486 Filing: 000159929826000015 The citation records this snapshot. The page link may show a newer release later.	−USD 76.89 million Calculation and evidence -76760000 − 128000 USD Exact free cash flow: -76888000 USD 2023-01-01 – 2023-12-31: -76760000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 128000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Summit Therapeutics Inc. · 2023-12-31 Summit Therapeutics Inc. (edgar:1599298) Free cash flow: -76888000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -76760000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000015/smmt-20251231.htm#1303077 Filing: 000159929826000015 Input fundies:CapitalExpenditure: 128000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000015/smmt-20251231.htm#1310486 Filing: 000159929826000015 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 221.32 million Exact value Exact value: -221315000 USD 2024-01-01 – 2024-12-31: -221315000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Summit Therapeutics Inc. · 2024-12-31 Summit Therapeutics Inc. (edgar:1599298) Net Income: -221315000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -221315000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000015/smmt-20251231.htm#1615086 Filing: 000159929826000015 The citation records this snapshot. The page link may show a newer release later.	−USD 142.11 million Exact value Exact value: -142106000 USD 2024-01-01 – 2024-12-31: -142106000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Summit Therapeutics Inc. · 2024-12-31 Summit Therapeutics Inc. (edgar:1599298) Operating Cash Flow: -142106000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -142106000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000015/smmt-20251231.htm#1302423 Filing: 000159929826000015 The citation records this snapshot. The page link may show a newer release later.	USD 139,000 Exact value Exact value: 139000 USD 2024-01-01 – 2024-12-31: 139000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Summit Therapeutics Inc. · 2024-12-31 Summit Therapeutics Inc. (edgar:1599298) Capital Expenditure: 139000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 139000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000015/smmt-20251231.htm#1309926 Filing: 000159929826000015 The citation records this snapshot. The page link may show a newer release later.	−USD 142.25 million Calculation and evidence -142106000 − 139000 USD Exact free cash flow: -142245000 USD 2024-01-01 – 2024-12-31: -142106000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 139000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Summit Therapeutics Inc. · 2024-12-31 Summit Therapeutics Inc. (edgar:1599298) Free cash flow: -142245000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T03:07:01Z Snapshot: 5c07185f27940da2b0e710a8290c9356e7d562f87a960cdf69e86dbeb9dc70ad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1599298?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -142106000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000015/smmt-20251231.htm#1302423 Filing: 000159929826000015 Input fundies:CapitalExpenditure: 139000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000015/smmt-20251231.htm#1309926 Filing: 000159929826000015 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

162 filings · 2,718 latest values · 2,718 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001599298, 1599298, SMMT, edgar:1599298

Also known as Summit Corp plc, Summit Therapeutics Inc., Summit Therapeutics plc

Summit Therapeutics Inc.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Net income

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2024 2024-01-01 – 2024-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation